PDGFRB and neoplasm: Lenvatinib could act on VEGFR 1-3, FGFR 1-4, PDGFR α, and other sites, and could effectively control tumor-related changes, including the control of tumor cell reproduction and the inhibition of tumor angiogenesis pathogenicity, which could effectively play an antitumor role (31, 32).